- Subjects with diagnosed hypertension receiving treatment with Norvasc 5 or 10 mg and
who also have 3 additional cardiovascular risk factors, including dyslipidemia.
- Subjects who are taking the following prohibited medications within 14 days of
screening: lipid-lowering therapy, calcium channel blocker other then Norvasc, >3
antihypertensive agents (including Norvasc)
- Subjects that have not been on a stable dose of Norvasc for at least 4 weeks
- Subjects with a history of coronary heart disease, stroke, or Pulmonary Vascular